UA6301A1 - Спосіб одержання похідних ціс-4-феніл-1,2,3,4-тетрагідра-1-нафтіламіна або його солей - Google Patents

Спосіб одержання похідних ціс-4-феніл-1,2,3,4-тетрагідра-1-нафтіламіна або його солей

Info

Publication number
UA6301A1
UA6301A1 UA2999197A UA2999197A UA6301A1 UA 6301 A1 UA6301 A1 UA 6301A1 UA 2999197 A UA2999197 A UA 2999197A UA 2999197 A UA2999197 A UA 2999197A UA 6301 A1 UA6301 A1 UA 6301A1
Authority
UA
Ukraine
Prior art keywords
tetrahydro
phenyl
salts
producing cis
naphthylamine derivatives
Prior art date
Application number
UA2999197A
Other languages
English (en)
Russian (ru)
Inventor
Маккован Віллард
Маккован Виллард
Армон Херберт Чарльз
Кеннет Кое Біллі
Кеннет Коэ Билли
Річард Краска Аллен
Ричард Краска Аллен
Original Assignee
Пфайзер Інк.
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22221931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA6301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Інк., Пфайзер Инк. filed Critical Пфайзер Інк.
Publication of UA6301A1 publication Critical patent/UA6301A1/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/21—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C07C209/14—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups
    • C07C209/16—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/28—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Предметом винаходу є спосіб отримання похідних цис-4-феніл-1,2,3,4-тетрагідро-1-нафтиламіну або їхніх солей. Сполука певної формули обробляється аміном у присутності кислого каталізатору, наприклад, чотирихлористого титану з подальшим відновленням отриманої проміжної сполуки боргідридом натрію і виділенням цільового продукту у вільному вигляді або у вигляді солі.
UA2999197A 1979-11-01 1980-10-28 Спосіб одержання похідних ціс-4-феніл-1,2,3,4-тетрагідра-1-нафтіламіна або його солей UA6301A1 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/090,240 US4536518A (en) 1979-11-01 1979-11-01 Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine

Publications (1)

Publication Number Publication Date
UA6301A1 true UA6301A1 (uk) 1994-12-29

Family

ID=22221931

Family Applications (2)

Application Number Title Priority Date Filing Date
UA2999197A UA6301A1 (uk) 1979-11-01 1980-10-28 Спосіб одержання похідних ціс-4-феніл-1,2,3,4-тетрагідра-1-нафтіламіна або його солей
UA3325759A UA6311A1 (uk) 1979-11-01 1980-10-28 Спосіб одержання похідних ціс-4-феніл-1,2,3,4-тетрагідро-1-нафталінаміна або їх солей

Family Applications After (1)

Application Number Title Priority Date Filing Date
UA3325759A UA6311A1 (uk) 1979-11-01 1980-10-28 Спосіб одержання похідних ціс-4-феніл-1,2,3,4-тетрагідро-1-нафталінаміна або їх солей

Country Status (38)

Country Link
US (1) US4536518A (uk)
EP (1) EP0030081B1 (uk)
JP (1) JPS605584B2 (uk)
KR (2) KR840002001B1 (uk)
AT (1) ATE2668T1 (uk)
AU (1) AU517357B2 (uk)
BA (2) BA97150B1 (uk)
BG (1) BG60333B2 (uk)
CA (1) CA1130815A (uk)
CS (4) CS238609B2 (uk)
DD (2) DD155615A5 (uk)
DE (2) DE3062225D1 (uk)
DK (1) DK153390C (uk)
EG (1) EG15527A (uk)
ES (2) ES8201949A1 (uk)
FI (1) FI68806C (uk)
GR (1) GR70781B (uk)
HK (1) HK82284A (uk)
HR (2) HRP930199B1 (uk)
HU (1) HU182224B (uk)
IE (1) IE50395B1 (uk)
IL (1) IL61374A (uk)
IN (2) IN159643B (uk)
LU (1) LU88330I2 (uk)
LV (2) LV5457A3 (uk)
MX (1) MX5980E (uk)
MY (1) MY8500326A (uk)
NL (1) NL940018I1 (uk)
NO (2) NO148996C (uk)
NZ (1) NZ195407A (uk)
PH (1) PH17319A (uk)
PT (1) PT72004B (uk)
SG (1) SG56584G (uk)
SI (2) SI8012798A8 (uk)
SU (2) SU1014467A3 (uk)
UA (2) UA6301A1 (uk)
YU (2) YU41951B (uk)
ZA (1) ZA806726B (uk)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
US4777288A (en) * 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
US4839104A (en) * 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
FR2623802B1 (fr) * 1987-11-26 1990-05-04 Lucien Laboratoires Derives d'amino-4 trifluoromethyl-1 tetralines. leur preparation et leur application en therapeutique
US4855500A (en) * 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
FR2632633B1 (fr) * 1988-06-08 1991-04-05 Delalande Sa Procede de preparation de 4-aryl-1-tetralones
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
EP0415612B1 (en) * 1989-08-30 1993-11-10 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
FR2665443B1 (fr) * 1990-08-03 1992-11-06 Lucien Laboratoires Derives d'amino-4-methyl-1-tetralines, leur preparation et leur application en therapeutique.
US5082970A (en) * 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114948D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
GB9114947D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5196607A (en) * 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5288916A (en) 1993-03-25 1994-02-22 Bend Research, Inc. Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
ES2108484T3 (es) * 1993-11-30 1997-12-16 Pfizer Procedimiento para la preparacion de una tetralona asimetrica.
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US6455736B1 (en) 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
AU5966196A (en) * 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
EP0759299B1 (en) * 1995-08-16 2000-04-26 Eli Lilly And Company Potentiation of serotonin response
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) * 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
CN1256085C (zh) * 1997-07-01 2006-05-17 美国辉瑞有限公司 舍曲林盐和舍曲林的缓释剂型
DE69713353D1 (de) * 1997-12-11 2002-07-18 Torcan Chemical Ltd Sertralin-Polymorph mit verbesserter Wasserlöslichkeit
IN191358B (uk) 1998-01-16 2003-11-29 Pfizer Prod Inc
WO1999046233A1 (fr) * 1998-03-09 1999-09-16 Sumika Fine Chemicals Co., Ltd. Derives de l'alcool benzylique
PT1064250E (pt) 1998-03-18 2004-09-30 Ciba Sc Holding Ag Processo para a hidrogenacao catalitica cis-selectiva ciclo-hexilidenaminas
FR2777000B1 (fr) * 1998-04-01 2002-09-27 Catalys Procede de preparation de la sertraline racemique
EP0957099B1 (en) 1998-04-15 2002-11-20 Pfizer Products Inc. Heterocyclic carboxamides
US6054614A (en) * 1998-04-23 2000-04-25 Ciba Specialty Chemicals Corporation Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
HU226423B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing a 1(2h)-naphtalene-1-ylidene derivative
HU226424B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing enantiomer mixture for preparation of sertraline
IN182588B (uk) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
PL348119A1 (en) * 1998-10-13 2002-05-06 Pfizer Prod Inc Sertraline oral concentrate
IL132500A0 (en) 1998-10-29 2001-03-19 Pfizer Prod Inc Stereoselective microbial reduction of a racemic tetralone
WO2000025598A1 (en) * 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
EP1632473A1 (en) * 1998-11-27 2006-03-08 Teva Pharmaceutical Industries Ltd Sertraline hydrochloride polymorphs
EP1133459B1 (en) * 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
AU2315400A (en) * 1999-03-01 2000-09-21 Middleton, Donald Stuart 1,2,3,4-tetrahydro-1-naphthalenamine compounds useful in therapy
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US6593496B1 (en) * 1999-06-09 2003-07-15 Pfizer Inc Process for preparing sertraline from chiral tetralone
IL147451A0 (en) * 1999-07-29 2002-08-14 Ciba Sc Holding Ag Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
IN185109B (uk) * 1999-09-01 2000-11-18 Torrent Pharmaceuticals Ltd
DK174219B1 (da) * 1999-10-27 2002-09-30 Gea Farmaceutisk Fabrik As Forbedret syntese af racemisk sertralin
TWI260315B (en) * 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
US6806386B1 (en) * 1999-11-16 2004-10-19 Ciba Specialty Chemicals Corporation Process for the preparation of ketimines
ES2241680T3 (es) * 1999-11-16 2005-11-01 Ciba Specialty Chemicals Holding Inc. Procedimiento para la preparacion de cetiminas.
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
HUP0204010A3 (en) 1999-12-21 2006-02-28 Teva Pharma Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and their use
JP2003518487A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク ヒドロゲル駆動型積層薬物製剤
IN187170B (uk) 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
SK14212002A3 (sk) * 2000-03-14 2003-07-01 Teva Pharmaceutical Industries Ltd. Spôsob prípravy (+)-cis-sertralínu
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
IN192343B (uk) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
ATE324365T1 (de) * 2000-08-31 2006-05-15 Pfizer Phenoxyphenylheterozyklen als serotonin- wiederaufnahmehemmer
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
EP1397343A1 (en) * 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
US6723878B2 (en) 2001-06-15 2004-04-20 Orion Corporation Fermion Method for preparing sertraline
WO2002102761A1 (en) * 2001-06-15 2002-12-27 Orion Corporation Fermion A novel process for the preparation of (is-cis) -4-(3, 4-dichlorophenyl) -1, 2, 3, 4 - tetrahydro-n-methyl-1-naphthalenamine
CN1606554B (zh) * 2001-10-12 2013-03-20 阿泽范药品公司 β-内酰胺后叶加压素V1a拮抗剂
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2003093217A1 (en) * 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
WO2004011413A1 (en) * 2002-07-29 2004-02-05 Cipla Limited Sertraline
PL376832A1 (pl) * 2002-11-07 2006-01-09 Torrent Pharmaceuticals Ltd. Sposób wytwarzania polimorficznej postaci chlorowodorku sertraliny
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
WO2004087732A2 (en) * 2003-03-11 2004-10-14 Sun Pharmaceutical Industries Limited Process for the preparation of (1s, 4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphthylamine
EP1583734A2 (en) * 2003-04-14 2005-10-12 Teva Pharmaceutical Industries Limited Hydrogenation of imine intermediates of sertraline with catalysts
US7186863B2 (en) * 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
US7173153B2 (en) * 2003-07-15 2007-02-06 Recordati Industria Chimica E. Farmaceutica S.P.A. Sertraline hydrochloride form II and methods for the preparation thereof
EP1648854A1 (en) * 2003-07-15 2006-04-26 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. Methods for preparing sertraline hydrochloride polymorphs
HU227495B1 (en) * 2003-07-21 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing of imine intermediate
CA2537804A1 (en) * 2003-09-05 2005-03-17 Teva Pharmaceutical Industries Ltd A recycling process for preparing sertraline
EP1663398B1 (en) 2003-09-12 2009-11-25 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
RU2006107534A (ru) * 2003-09-12 2007-09-20 Уорнер-Ламберт Компани Ллс (Us) Комбинация, включающая альфа-2-дельта-лиганд анд и ssri и/или snri, для лечения депрессии и тревожного расстройства
ES2319539T3 (es) * 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv Compuestos heterociclicos condensados como moduladores del receptor de serotonina.
RU2376279C2 (ru) * 2003-11-04 2009-12-20 Сипла Лимитед Способ получения полиморфов ингибитора повторного захвата серотонина (варианты)
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
US20050250803A1 (en) * 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
CA2565159A1 (en) * 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US7345201B2 (en) * 2005-02-23 2008-03-18 Teva Pharmaceutical Industries, Ltd. Processes for preparing sertraline
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
JP2006265169A (ja) * 2005-03-24 2006-10-05 Tokuyama Corp アルキリデンコハク酸化合物の製造方法
GB0507090D0 (en) * 2005-04-07 2005-05-11 Sandoz Ag Process for preparing polymorphic form ll of sertraline hydrochloride
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
BRPI0610785A2 (pt) * 2005-04-22 2016-09-13 Wyeth Corp polimorfo cristalino, processo para preparar o mesmo, forma cristalina, composição, e, métodos para tratar uma doença, distúrbios, e uma condição
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
CA2604916A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AU2006239922A1 (en) 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
CA2605587A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
WO2006129324A2 (en) * 2005-06-03 2006-12-07 Hetero Drugs Limited A highly stereoselective synthesis of sertraline
US20070100165A1 (en) * 2005-06-09 2007-05-03 Ronen Borochovitz Process for preparation of sertraline hydrochloride form I
WO2007002597A2 (en) * 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
CA2614289A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
DK1910346T3 (da) * 2005-07-19 2019-05-27 Azevan Pharmaceuticals Inc Beta-lactamyl fenylalanin, cystein og serin vasopressin antagonist
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
JP5438975B2 (ja) * 2006-01-06 2014-03-12 サノビオン ファーマシューティカルズ インク テトラロン系モノアミン再取り込み阻害剤
WO2007087387A1 (en) * 2006-01-23 2007-08-02 Teva Pharmaceutical Industries Ltd. A recycling process for preparing sertraline
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
WO2007119247A2 (en) * 2006-04-17 2007-10-25 Unichem Laboratories Limited Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride)
TR200808115T1 (tr) * 2006-04-28 2009-03-23 Sandoz Ag 4(S,R)-(3,4-diklorofenil)-3,4-dihidro-l(2H)-naftalin-l-ilid n]metilamin'ın Hazırlanması için Proses.@
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
EP2029517A2 (en) * 2006-06-13 2009-03-04 Ramot at Tel-Aviv University Ltd. Antiproliferative compounds, compositions and methods of use
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
AU2008204800A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US20090062399A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sertraline
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9260413B2 (en) * 2010-03-04 2016-02-16 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2011163231A2 (en) 2010-06-21 2011-12-29 Theracos, Inc. Combination therapy for the treatment of diabetes
PL2587919T3 (pl) 2010-07-01 2018-05-30 Azevan Pharmaceuticals, Inc. Sposoby leczenia zespołu stresu pourazowego
WO2012123922A1 (en) 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101340270B1 (ko) * 2011-11-10 2013-12-10 보령제약 주식회사 (+)-시스-서트랄린의 선택적인 제조방법
PE20150733A1 (es) * 2012-10-18 2015-05-17 Hoffmann La Roche Derivados de etinilo como moduladores de la actividad del receptor mglur5
MX2021005502A (es) 2014-03-28 2023-01-16 Azevan Pharmaceuticals Inc Composiciones y metodos para tratar enfermedades neurodegenerativas.
US10266481B2 (en) 2014-06-20 2019-04-23 Council Of Scientific & Industrial Research Organocatalytic asymmetric synthesis of antidepressants
WO2016023832A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
WO2016023825A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180342B1 (en) * 2014-08-11 2019-06-26 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
ES2938409T3 (es) 2015-09-21 2023-04-10 Johnson & Son Inc S C Sistema para mezclar y suministrar
AU2018333051B2 (en) 2017-09-15 2024-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
WO2020043716A1 (en) 2018-08-27 2020-03-05 Katholieke Universiteit Leuven Pharmacological targeting of de novo serine/glycine synthesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887509A (en) * 1956-11-05 1959-05-19 Lilly Co Eli Hydroxybenzoyl benzoate salt of beta-(o-chlorophenyl)-beta-hydroxyethyl isopropylamine
US3704323A (en) * 1969-12-23 1972-11-28 Squibb & Sons Inc Indane derivatives
US4029731A (en) * 1974-11-06 1977-06-14 Pfizer Inc. Aminophenyltetralin compounds
US4045488A (en) * 1974-11-06 1977-08-30 Pfizer Inc. Aminophenyltetralin compounds

Also Published As

Publication number Publication date
NO148996B (no) 1983-10-17
ES496443A0 (es) 1982-01-16
LV5456A3 (lv) 1994-03-10
US4536518A (en) 1985-08-20
HK82284A (en) 1984-11-09
ZA806726B (en) 1981-10-28
MX5980E (es) 1984-09-12
KR840002001B1 (ko) 1984-10-27
PH17319A (en) 1984-07-20
DD155615A5 (de) 1982-06-23
EG15527A (en) 1987-04-30
GR70781B (uk) 1983-03-23
IL61374A (en) 1983-10-31
SU1034602A3 (ru) 1983-08-07
FI803398L (fi) 1981-05-02
HU182224B (en) 1983-12-28
IE802259L (en) 1981-05-01
YU279880A (en) 1983-09-30
IL61374A0 (en) 1980-12-31
CS238618B2 (en) 1985-12-16
DE3062225D1 (en) 1983-04-07
IN159644B (uk) 1987-05-30
UA6311A1 (uk) 1994-12-29
NO148996C (no) 1984-01-25
CA1130815A (en) 1982-08-31
MY8500326A (en) 1985-12-31
HRP930199B1 (en) 1996-02-29
SU1014467A3 (ru) 1983-04-23
ES506892A0 (es) 1982-09-01
ES8207123A1 (es) 1982-09-01
SI8310672A8 (en) 1996-04-30
CS354291A3 (en) 1992-12-16
DK153390B (da) 1988-07-11
NL940018I1 (nl) 1994-10-17
KR830004202A (ko) 1983-07-06
NO1996011I1 (no) 1996-09-24
AU517357B2 (en) 1981-07-23
AU6389780A (en) 1981-05-07
CS238609B2 (en) 1985-12-16
FI68806C (fi) 1985-11-11
YU67283A (en) 1983-10-31
NO803258L (no) 1981-05-04
LU88330I2 (fr) 1994-05-04
DD203045A5 (de) 1983-10-12
YU42846B (en) 1988-12-31
FI68806B (fi) 1985-07-31
ES8201949A1 (es) 1982-01-16
LV5457A3 (lv) 1994-03-10
NZ195407A (en) 1984-05-31
PT72004A (en) 1980-11-01
ATE2668T1 (de) 1986-03-15
EP0030081A1 (en) 1981-06-10
SG56584G (en) 1985-03-08
PT72004B (en) 1981-08-31
EP0030081B1 (en) 1983-03-02
KR840002000B1 (ko) 1984-10-27
DK395280A (da) 1981-05-02
CS238617B2 (en) 1985-12-16
DE19775012I2 (de) 2001-02-08
IN159643B (uk) 1987-05-30
YU41951B (en) 1988-02-29
JPS5686137A (en) 1981-07-13
BA97150B1 (bs) 1998-12-28
HRP931527B1 (en) 1996-04-30
JPS605584B2 (ja) 1985-02-12
DK153390C (da) 1988-12-05
IE50395B1 (en) 1986-04-16
BA97149B1 (bs) 1998-12-28
BG60333B2 (bg) 1994-11-30
SI8012798A8 (sl) 1994-12-31

Similar Documents

Publication Publication Date Title
UA6301A1 (uk) Спосіб одержання похідних ціс-4-феніл-1,2,3,4-тетрагідра-1-нафтіламіна або його солей
ES2013801A6 (es) Procedimiento de preparacion de derivados de 4h-1-benzopiran-4-ona o sus sales.
ATE36859T1 (de) 4'-demethyl-4-epipodophyllotoxin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ES8106513A1 (es) Procedimiento para la preparacion de sales de la (+)-cate- quina
ES8105709A1 (es) Un procedimiento para la preparacion de derivados de azeti din-2-ona.
HUT46936A (en) Process for producing cyclooktaamilose
MY110450A (en) Imidazolylmethyl-pyridines, their production their use as pharmaceuticals and pharmaceutical compositions containing them
ES8507123A1 (es) Procedimiento para la preparacion de un derivado de 4-alquil-2-hidroxi-3-metil-2-fenil-morfolina
ES8202341A1 (es) Un procedimiento para preparar derivados de la ergolin.
ES405479A1 (es) Un procedimiento para la preparacion de derivados de benzo-diacepina.
ES8504252A1 (es) Un procedimiento para producir derivados de antraciclina
DE3061787D1 (en) Process for preparing derivatives of 6-amino-6-desoxy-2,3-0-isopropylidene-alpha-l-sorbofuranose and intermediates of the process
ES2017127A6 (es) Un metodo para la inhibicion del crecimiento microbiano en medio acuoso.
GB1283452A (en) Substituted 1,3-dialkylpyrrolidines and processes for their production
ES8603434A1 (es) Un procedimiento para la produccion del 1, 2, 4-triazolilpropanol
ES8303299A1 (es) Procedimiento de preparacion de un nuevo derivado de acido benzamido-alquil-hidroxamico.
GB1445675A (en) Cyclohexanediol derivative and process for preparing the same
GB1042894A (en) 3-cyanopyrrolidines
ES8203016A1 (es) Un procedimiento para la preparacion de una solucion acuosa inyectable de sales de metales alcalinas de acido canrenoicoy de furosemida.
KR790000338B1 (en) Process for preparation of penicillin derivatives
GB1477263A (en) Thiamindisulphidemono-orotate and process for its preparation
GR852126B (uk)
ES8302627A1 (es) Procedimiento de preparacion de un nuevo derivado de 5-hidroxi-l-triptofano.
GB941751A (en) 6-glycosylthio-9-glycosylpurines and a method for making them
JPS55139366A (en) Piperazine compound, its salt, and their preparation